Children's Hospital Medical Center, Cincinnati
Clinical trials sponsored by Children's Hospital Medical Center, Cincinnati, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- First human trial of Gene-Edited lung cells for rare breathing disorder Results expected Sep 2026 (estimated)
- Supercharged immune cells take on post-transplant viruses Results expected Sep 2026 (estimated)
- Foster care study tests new parenting program to stop behavior issues early Results expected Sep 2026 (estimated)
- New study follows 100 infants to unlock cerebral Palsy's early secrets Results expected Sep 2026 (estimated)
- New MRI technique could revolutionize cystic fibrosis care Results expected Sep 2026 (estimated)
-
Violet light lamp tested to stop Kids' eyesight from getting worse
Disease control Stopped earlyThis study tests whether using a violet light lamp at home can slow the progression of myopia (nearsightedness) in children. 72 kids aged 5 to 12 will use either a violet light lamp or a regular white light lamp for 12 months. Researchers will measure changes in eye length and vi…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug hope for lung damage after transplant falls short
Disease control Stopped earlyThis study tested the drug ruxolitinib to treat early lung damage in children and adults who had a stem cell transplant. Lung problems like bronchiolitis obliterans can be serious and hard to detect early. The trial aimed to see if adding ruxolitinib to standard care could improv…
Phase 2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Computer-tailored drug dosing aims to tame Crohn's in kids
Disease control Stopped earlyThis trial tested whether a computer program that customizes infliximab doses based on blood tests can help children and young adults with Crohn's disease reach better drug levels than standard dosing. Only 6 participants were enrolled before the study was stopped early. The goal…
Phase 2/3 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Steroid-Free hope? early trial of ruxolitinib for young GVHD patients ends prematurely
Disease control Stopped earlyThis pilot study tested whether the drug ruxolitinib could be used as the first treatment for chronic graft-versus-host disease (cGVHD) in children and young adults, instead of the usual high-dose steroids. The goal was to see if it could control the disease while avoiding steroi…
Phase 1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC